Report Subject - Generics/Biosimilars - Page 1

Learn More Biomarkers and Companion diagnostics: Payer Insights

What do you need to do to get payer support for companion diagnostics and biomarkers? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand...

Compare
Learn More Trends in Investment by Big Pharma

What direction are big pharma investments taking? The investment decisions made by the biggest players in core disease areas drive market trends—so it's crucial to understand where the big money is going and why...

Compare
Learn More Biosimilars: The Importance of Real-World Evidence (2019)

Are you generating the right RWE to influence the right stakeholders? As the biosimilar sector continues to evolve and experience of their use deepens, what role should real-world evidence (RWE) now take in stakeholder...

Compare
Learn More Pharma-Tech Partnerships: Key Success Factors

What does an ideal Pharma-Tech partnership look like? Learn from Merck, Sanofi, Boehringer Ingelheim and UCB With tech companies making their presence felt in the health market and a demand for greater efficiency...

Compare
Learn More Commercialisation of Biosimilars: Current Best Practice and Future Trends

The key to commercial success for biosimilars? Find out what the experts say The biosimilars market is in a state of flux as key players in the US and Europe actively seek to improve perceptions, shape the market, and...

Compare
Learn More Orphan Drugs: The Importance of Real-World Evidence

Current expert thinking on how real-world evidence can refine orphan drug research, demonstrate stakeholder value and prove clinical effectiveness. Alarmed at the number of often highly-priced orphan drugs coming to...

Compare
Learn More The State of Pharma Digital Transformation

How digitally mature is pharma? What progress has pharma made to embrace the digital age? Are digital strategies robust enough? Are appropriate capabilities and organisational structures in place? How culturally ready...

Compare
Learn More Time to Market: Accelerating Market Access

Building the most effective strategy for fast track market access Getting to market faster clearly has benefits, but there are also potential downsides for drug companies too. You need to know the options and consider...

Compare
Learn More Biosimilars: US Payer Insights (2019)

What do payers see as critical to unlocking the stalled US biosimilar sector? How do payers view the trends in the sluggish US biosimilar market and what initiatives do they want from pharma? Originator companies are...

Compare
Learn More A new Era in Pharma Marketing: Delivering Content-Driven Experiences

Are you locked in a traditional product marketing mind set? Time to move on... How can you provide better support and awareness to HCPs and patients for your brands? Content marketing may be the answer. Advocates argue...

Compare
Learn More Biologics Life Cycle Management: Tactics and Strategies in the Biosimilars Era

The biologics competitive landscape is at a critical stage of development. How will you respond? Biosimilars are on the offensive across Europe and beyond. With the recent launches of multiple new biosimilars to compete...

Compare
Learn More Pharma-patient engagement: Patient centricity comes of age

Are you truly patient-centric or just ticking boxes? Find out how your strategy compares Until relatively recently, patient centricity was commonly seen as just a useful talking point and the catalyst for some...

Compare
Learn More Orphan Drugs: US Payer Perspectives

So what will persuade US payers to better support orphan drugs? US payer concern at the number of new orphan drugs coming to market, often with eye watering prices attached, can obscure a more positive message: payers...

Compare
Learn More Orphan Drugs: European Payer Perspectives

European payers reveal how pharma can build trust and gain their support for orphan drug products European payers are concerned about orphan drugs citing unjustified high prices and a lack of evidence of utility and...

Compare
Learn More Do Payers Really Want Pay-for-Performance?

Explore the latest payer views and requirements for pay for performance When it comes to payment for performance (P4P), it's notoriously difficult to know exactly what payers want to see. Useful face-to-face payer...

Compare
Learn More Patient Journey Mapping for Market Access

Which market access teams will be first to unlock the power of patient journey mapping? There's no doubt that market access has evolved significantly in recent years, but there is so much more to be done. What some...

Compare

Browse by